Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Urologic Oncology
|
April 4, 2026
Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience
Alireza Ghoreifi, Christopher J Hoimes, Sundhar Ramalingam, et al.
Prostate Cancer and Prostatic Diseases
|
December 13, 2017
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Michael S Humeniuk, Rajan T Gupta, Patrick Healy, et al.
Urologic Oncology
|
January 28, 2017
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer
Sundhar Ramalingam, Michael S Humeniuk, Rachel Hu, et al.
JTO Clinical and Research Reports
|
June 20, 2022
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial
Jeffrey M Clarke, Lin Gu, Xiaofei F Wang, et al.
Cancer Medicine
|
July 5, 2019
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer
Matthew D Tucker, Jason Zhu, Daniele Marin, et al.
Research Square
|
July 10, 2026
Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer
Andrew Armstrong, Tara Seibert, Jane McKenzie, et al.
European Urology Oncology
|
July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial
Tian Zhang, Lauren Howard, Bridget F Koontz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Tracy L Rose, Michael R Harrison, Allison M Deal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
Robert J Motzer, Eric Jonasch, Shawna Boyle, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Urologic Oncology
|
April 4, 2026
Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience
Alireza Ghoreifi, Christopher J Hoimes, Sundhar Ramalingam, et al.
Prostate Cancer and Prostatic Diseases
|
December 13, 2017
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Michael S Humeniuk, Rajan T Gupta, Patrick Healy, et al.
Urologic Oncology
|
January 28, 2017
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer
Sundhar Ramalingam, Michael S Humeniuk, Rachel Hu, et al.
JTO Clinical and Research Reports
|
June 20, 2022
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial
Jeffrey M Clarke, Lin Gu, Xiaofei F Wang, et al.
Cancer Medicine
|
July 5, 2019
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer
Matthew D Tucker, Jason Zhu, Daniele Marin, et al.
Research Square
|
July 10, 2026
Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer
Andrew Armstrong, Tara Seibert, Jane McKenzie, et al.
European Urology Oncology
|
July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial
Tian Zhang, Lauren Howard, Bridget F Koontz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Tracy L Rose, Michael R Harrison, Allison M Deal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
Robert J Motzer, Eric Jonasch, Shawna Boyle, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Page
of 3